Top Page
Noronex Ltd.
(Sydney:NRX)
Noronex Ltd. (NRX) vs. iShares MSCI Australia ETF (EWA)
Noronex Ltd. Business Overview & Revenue Model
Noronex Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 368.16K | 368.16K | 40.68K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 368.16K | 368.16K | 40.68K | 0.00 | 0.00 | 0.00 |
| EBITDA | -1.08M | -1.08M | -2.52M | 36.40K | 148.07K | 25.73K |
| Net Income | -3.13M | -3.13M | -2.51M | -3.35M | -5.55M | -2.15M |
Balance Sheet | ||||||
| Total Assets | 2.20M | 2.20M | 3.81M | 3.32M | 5.05M | 5.72M |
| Cash, Cash Equivalents and Short-Term Investments | 1.01M | 1.01M | 913.58K | 393.75K | 2.11M | 3.01M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 1.22M | 1.22M | 754.42K | 424.52K | 468.48K | 259.97K |
| Stockholders Equity | 951.15K | 951.15K | 3.02M | 2.85M | 4.36M | 5.11M |
Cash Flow | ||||||
| Free Cash Flow | -3.68M | -3.68M | -2.36M | -3.12M | -5.36M | -2.06M |
| Operating Cash Flow | -3.68M | -3.68M | -2.36M | -3.12M | -5.28M | -1.80M |
| Investing Cash Flow | -42.61K | -42.61K | 412.06K | 0.00 | -80.00K | -703.93K |
| Financing Cash Flow | 3.78M | 3.78M | 2.47M | 1.42M | 4.46M | 4.02M |
Noronex Ltd. Technical Analysis
Noronex Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
49 Neutral | €195.57M | -25.36 | -73.21% | ― | ― | -11.29% | |
48 Neutral | AU$9.37M | -2.46 | -157.73% | ― | ― | 6.15% | |
46 Neutral | AU$5.14M | -0.95 | -25.55% | ― | ― | -34.62% | |
46 Neutral | AU$169.88M | -1.15 | ― | ― | -57.00% | -1789.13% | |
44 Neutral | AU$260.84M | -3.40 | ― | ― | ― | ― |
Noronex Ltd. Corporate Events
Noronex Limited has announced the progression of the sale of its non-core Witvlei Project in Namibia, receiving a non-refundable deposit of A$200,000 from Joint Era Mining Co., Limited. This transaction, valued at A$4.5 million, allows Noronex to focus on its extensive copper portfolio, including projects in collaboration with South32. The sale is part of Noronex’s strategy to concentrate on its core assets, potentially enhancing its industry positioning and resource management.
Noronex Limited has announced a change in the director’s interest notice, specifically regarding Robert Klug’s holdings. Mr. Klug has acquired 5,000,000 unquoted options exercisable at $0.025 each on or before October 1, 2027, increasing his total holdings to include these new options. This change reflects the issuance of incentive options as part of a previously noted meeting, potentially impacting the company’s leadership incentives and aligning director interests with company performance.
Noronex Limited has announced a change in the interests of its director, Piers Lewis, involving the acquisition of 5,000,000 unquoted options exercisable at $0.025 each on or before October 1, 2027. This issuance of incentive options, as referenced in the Notice of Meeting dated October 10, 2025, reflects a strategic move to potentially enhance the director’s stake in the company, which could influence the company’s governance and decision-making processes.
Noronex Limited has announced a change in the interests of its director, David Prentice, involving the acquisition of 5,000,000 unquoted options. These options are exercisable at $0.025 each and are set to expire on 1 October 2027. This change reflects an issuance of incentive options as per the Notice of Meeting dated 10 October 2025, indicating a strategic move to align the director’s interests with the company’s long-term goals.
Noronex Limited has announced the issuance of 5,333,333 fully paid ordinary shares, which are exempt from the on-sale restrictions under the Corporations Act 2001. This move is part of the company’s compliance with regulatory requirements, ensuring transparency and maintaining its obligations under the Act. The announcement indicates that there is no undisclosed information that would impact investors’ assessments of the company’s financial position or the rights attached to the shares.
Noronex Limited has announced the issuance of 15 million unquoted options, set to expire on October 1, 2027, at an exercise price of $0.025. This issuance, part of an employee incentive scheme, is intended to enhance employee engagement and align their interests with the company’s growth objectives, potentially impacting the company’s operational dynamics and stakeholder interests.
Noronex Limited has announced the issuance of 3,000,000 performance rights and 3,000,000 options as part of an employee incentive scheme. This move is aimed at motivating and retaining key personnel, potentially strengthening the company’s operational capabilities and aligning employee interests with shareholder objectives.
Noronex Limited has announced the issuance of 500,000 ordinary fully paid shares on November 28, 2025, for investor relations and public relations services. This move is part of their strategic efforts to enhance market visibility and engagement, potentially impacting their stakeholder relationships and market positioning.
Noronex Limited has announced the issuance of 500,000 ordinary fully paid shares on November 28, 2025, as part of an agreement for IR/PR services. This move signifies a strategic effort by Noronex to enhance its investor relations and public relations capabilities, potentially impacting its market presence and stakeholder engagement.
Noronex Limited has announced the issuance of 3,000,000 fully paid ordinary securities, which are set to be quoted on the Australian Securities Exchange (ASX) under the code NRX. This move is part of the company’s strategy to enhance its capital structure and potentially increase its market presence, offering stakeholders an opportunity to invest in its growth trajectory.
Noronex Limited has announced promising initial assay results from its ongoing 7,000-meter Reverse Circulation drilling program at the Powerline Copper Project in Namibia. The drilling, funded through an agreement with South32, has identified a significant zone of copper-silver mineralization, validating the company’s geological model and exploration strategy. The project aims to explore the D’Kar-NPF contact horizon, with further drilling planned to assess the potential extensions of the mineralized zone. These findings are expected to enhance Noronex’s position in the copper mining sector and provide valuable insights for future exploration efforts.
Noronex Limited has announced a proposed issue of 20,000,000 unlisted options, exercisable at $0.024 and expiring 24 months from the issue date. This move is part of a placement or other type of issue, with the proposed issue date set for December 24, 2025. The announcement may impact the company’s financial structure and market positioning by potentially increasing its capital base and providing additional resources for its operations.
Noronex Limited has announced the sale of its non-core Witvlei Project in Namibia to Joint Era Mining Co., Limited for A$4.5 million. This strategic divestment allows Noronex to streamline its operations and focus on its core projects in the Kalahari Copper Belt. The proceeds from the sale will be used to strengthen the company’s balance sheet and fund exploration at the Etango North Uranium Project, positioning Noronex for future growth and development opportunities.
Noronex Ltd. has adopted a new constitution as of November 30, 2022, with amendments made on November 10, 2025. The updated constitution outlines the company’s governance structure, including share capital, rights, and securities holding, which are crucial for its operational and strategic direction.
Noronex Limited announced the successful passing of all resolutions at its Annual General Meeting, including the adoption of the remuneration report, re-election of David Prentice, and approval of various incentive options and mandates. This outcome reflects strong shareholder support and positions the company to continue its strategic initiatives, potentially impacting its operational efficiency and market competitiveness.
Noronex Limited has announced significant progress in its exploration activities, particularly in Namibia and Botswana. The company has reported promising copper intercepts from its Fiesta Copper Project in Namibia and has initiated a 7,000m RC drilling program at the Powerline Project. Additionally, Noronex has expanded its strategic alliance with South32 to include new tenements in Botswana, with a commitment of up to A$5 million over five years. The company has also identified new uranium targets at the Etango North Uranium Project and completed a $750,000 placement to support ongoing exploration efforts. These developments are expected to strengthen Noronex’s position in the mining sector and potentially lead to new discoveries.
Noronex Limited has commenced a significant Reverse Circulation (RC) drilling campaign at its Cgae Cgae Copper Project in Botswana, in partnership with South32. The project aims to explore new large-scale copper discoveries beneath the Kalahari sands, leveraging geological models that suggest similarities to the Central African Copper Belt. This initiative is part of a broader strategic alliance with South32, which includes a commitment of A$1 million per quarter for exploration activities in the region. The drilling program represents a strategic move to unlock the copper potential of this under-explored area, potentially strengthening Noronex’s position in the copper mining sector.
Noronex Limited has entered into an earn-in agreement with South32, allowing the latter to acquire a 60% interest in Noronex’s Cgae Cgae Copper Project in Botswana by investing A$5 million over five years. This strategic partnership aims to enhance copper exploration in the Kalahari Copper Belt, with a 3,000m RC drilling program set to begin soon. This collaboration is expected to bolster Noronex’s exploration capabilities and strengthen its position in the copper mining sector, potentially leading to significant discoveries and advancements in the region.
Noronex Limited has announced the issuance of 53,571,429 fully paid ordinary shares, which are exempt from the on-sale restrictions under section 708A(5) of the Corporations Act 2001. This move is part of the company’s compliance with the Act, ensuring transparency and providing investors with necessary information for informed decision-making, potentially impacting its market operations and investor relations.
Noronex Limited has announced the issuance of 53,571,429 fully paid ordinary shares, which will be quoted on the Australian Securities Exchange (ASX) under the code NRX. This move is part of a previously announced transaction, potentially enhancing the company’s capital structure and market presence, thereby offering new opportunities for stakeholders and investors.
Noronex Limited has announced the details of its upcoming Annual General Meeting (AGM) scheduled for November 10, 2025. The company is encouraging shareholders to participate in the voting process, either by proxy or in person, and emphasizes the use of electronic communications to reduce costs and improve efficiency. The AGM will be held at the company’s office in Subiaco, Western Australia, and any changes to the meeting arrangements will be communicated via the ASX Market Announcements Platform and the company’s website.